Patents Assigned to Fresenius Kabi Oncology Limited
-
Publication number: 20230295077Abstract: The present invention relates to an improved process for the preparation of a compound of Formula (1), The invention also provides improved processes for the preparation of intermediates used in the synthesis of Formula (1). The compound of Formula (1) is used in the synthesis of Semaglutide.Type: ApplicationFiled: April 9, 2021Publication date: September 21, 2023Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Maneesh Kumar PANDEY, Sonu Prasad SHUKLA, Sachin NAIN, Sandeep SANDEEP, Sridhar MALE, Sarbjot Singh SOKHI, Govind SINGH, Saswata LAHIRI, Walter CABRI
-
Publication number: 20220211705Abstract: The present invention relates to a tablet comprising Afatinib or a pharmaceutically acceptable salt thereof, wherein the tablet is obtained by direct compression. The present invention further relates to a process for manufacturing a tablet of the invention as well as the use of the tablet of the invention.Type: ApplicationFiled: March 22, 2022Publication date: July 7, 2022Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Rajesh KHANNA, Neeraj KUMAR, Vijay Kumar SHARMA, Ankit GAUR, Dhiraj KHATTAR
-
Publication number: 20220151923Abstract: The present invention relates to a stable liquid pharmaceutical composition of pemetrexed for parenteral administration. The invention provides composition comprising pemetrexed diacid, an organic amine and cyclodextrin. The composition may further comprise an inert gas. The composition can be ready to use infusion solution of pemetrexed diacid or liquid concentrate formulation to be diluted before administration to the patient. The present invention further relates to a process for manufacturing the compositions as well as use of the compositions of the invention for the treatment of malignant pleural mesothelioma and non-small cell lung cancer.Type: ApplicationFiled: September 27, 2021Publication date: May 19, 2022Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Dhiraj KHATTAR, Rajesh KHANNA, Abhilasha YADAV, Vikas BHANDARI, Sameer Ramanlal MODI, . HEMLATA
-
Publication number: 20210371410Abstract: The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof using lesser reaction steps and also eliminating expensive and time-consuming column chromatography. The invention also relates to novel polymorphic forms of Alectinib and Alectinib hydrochloride.Type: ApplicationFiled: August 16, 2021Publication date: December 2, 2021Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Vinod Singh TOMAR, Abul AZIM, Nitin GUPTA, Saswata LAHIRI, Walter CABRI
-
Publication number: 20210024506Abstract: The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.Type: ApplicationFiled: October 1, 2020Publication date: January 28, 2021Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Walter CABRI, Saswata LAHIRI, Bhuwan Bhaskar MISHRA, Abul AZIM, Nilendu PANDA, Poli Reddy BHAVANAM, Krishanu RAY, Nikunj KACHHADIA, Kumber SINGH
-
Publication number: 20200277295Abstract: The invention relates to a process for the preparation of ribociclib of formula V or its salts. The invention provides novel crystalline forms of ribociclib succinate and ribociclib trifluoroacetate. The present invention also relates to pharmaceutical compositions comprising a crystalline form of ribociclib succinate and at least a pharmaceutically acceptable carrier. It further relates to the use of such compositions in the treatment of cancer.Type: ApplicationFiled: October 26, 2018Publication date: September 3, 2020Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Sarbjot Singh SOKHI, Govind SINGH, Saswata LAHIRI, Maneesh Kumar PANDEY, Raj Narayan TIWARI, Sonu SHUKLA, Sachin MUSMADE, Heena DUA, Walter CABRI
-
Publication number: 20200246263Abstract: The present invention relates to a stable liquid pharmaceutical composition of pemetrexed for parenteral administration. The invention provides composition comprising pemetrexed diacid, an organic amine and cyclodextrin. The composition may further comprise an inert gas. The composition can be ready to use infusion solution of pemetrexed diacid or liquid concentrate formulation to be diluted before administration to the patient. The present invention further relates to a process for manufacturing the compositions as well as use of the compositions of the invention for the treatment of malignant pleural mesothelioma and non-small cell lung cancer.Type: ApplicationFiled: August 28, 2018Publication date: August 6, 2020Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Dhiraj KHATTAR, Rajesh KHANNA, Abhilasha YADAV, Vikas BHANDARI, Sameer Ramanlal MODI, Hemlata
-
Publication number: 20200138817Abstract: The present invention relates to a tablet comprising Afatinib or a pharmaceutically acceptable salt thereof, wherein the tablet is obtained by direct compression. The present invention further relates to a process for manufacturing a tablet of the invention as well as the use of the tablet of the invention.Type: ApplicationFiled: October 30, 2019Publication date: May 7, 2020Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Rajesh KHANNA, Neeraj KUMAR, Vijay Kumar SHARMA, Ankit GAUR, Dhiraj KHATTAR
-
Publication number: 20200140427Abstract: The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof using lesser reaction steps and also eliminating expensive and time-consuming column chromatography. The invention also relates to novel polymorphic forms of Alectinib and Alectinib hydrochloride.Type: ApplicationFiled: July 4, 2018Publication date: May 7, 2020Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Vinod Singh TOMAR, Abul AZIM, Nitin GUPTA, Saswata LAHIRI, Walter CABRI
-
Publication number: 20200031850Abstract: The present invention relates to an improved process for the preparation of a compound of formula (I), wherein PG1 may be independently selected from tert-butyloxycarbonyl (Boc), phthaloyl, 9-fluorenylmethyloxycarbonyl (Fmoc), triphenylmethyl (Trityl), carboxybenzyl (Cbz), trifluoroacetyl, benzyl (Bn), benzylidene, methanesulfonyl (Mesyl), toluene sulfonyl (Tosyl) or acyl; its isolation as solid and use for the preparation of the compound of formula (IV), in particular the compound of formula (IV) i.e. [(1R)-3-methyl-1[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid with more than 99.95% chiral purity, as measured by HPLC.Type: ApplicationFiled: February 19, 2018Publication date: January 30, 2020Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Maneesh Kumar PANDEY, Raj Narayan TIWARI, Sonu SHUKLA, Sarbjot Singh SOKHI, Govind SINGH, Saswata LAHIRI, Walter CABRI
-
Publication number: 20190218249Abstract: The present invention relates to a process for the purification of compound of formula II, wherein X may be independently selected from trifluoroacetic acid, hydrochloric acid, hydrobromic acid, p-toluene sulfonic acid and phosphoric acid; its isolation as solid and use for the preparation of carfilzomib.Type: ApplicationFiled: September 13, 2017Publication date: July 18, 2019Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Walter CABRI, Saswata LAHIRI, Govind SINGH, Sarbjot Singh SOKHI, Maneesh Kumar PANDEY, Raj Narayan TIWARI, Sonu Prasad SHUKLA
-
Patent number: 10253066Abstract: The present invention relates to a process for the purification of Carfilzomib of Formula I that reduces the level of an acetamide impurity of Formula II preferably below 0.10 wt %.Type: GrantFiled: December 1, 2015Date of Patent: April 9, 2019Assignee: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Maneesh Kumar Pandey, Raj Narayan Tiwari, Sarbjot Singh Sokhi, Govind Singh, Saswata Lahiri, Walter Cabri
-
Patent number: 9968608Abstract: A pharmaceutical composition of Pemetrexed represented by formula (I), which is a liquid ready to use solution formulation or a lyophilized pharmaceutical composition for parenteral administration comprising a pharmaceutically acceptable organic amine, an inert gas and optionally containing at least one or more pharmaceutically acceptable excipients. Also provided are processes for preparation of the ready to use solution formulation or lyophilized pharmaceutical composition of the present invention.Type: GrantFiled: July 1, 2016Date of Patent: May 15, 2018Assignee: Fresenius Kabi Oncology LimitedInventors: Dhiraj Khattar, Rajesh Khanna, Mukti Yadav, Krishanu Burman
-
Patent number: 9872873Abstract: The present invention relates to a process of preparing a stable pharmaceutical composition of compounds which are susceptible to hydrolysis comprising a. Addition of required quantity of pharmaceutically acceptable lyophilization excipients optionally in Water for Injection in a formulation vessel; b. Addition of organic solvent to form a appropriate proportion of aqueous and organic solvent; c. Maintaining the temperature of the formulation vessel from the range ?5±1° C. to ?5±3° C.; d. Addition of required quantity of compound susceptible to hydrolysis to form a solution and lyophilizing the solution.Type: GrantFiled: March 29, 2012Date of Patent: January 23, 2018Assignee: Fresenius Kabi Oncology LimitedInventors: Dhiraj Khattar, Rajesh Khanna, Sanjay Motwani, Minakshi Garg, Vikas Chandel, Mukti Yadav, Vijay Kumar Kyama, Vikas Bhandari
-
Patent number: 9669048Abstract: Described herein are ready to use, non-aqueous pharmaceutical compositions comprising 5-aza-2?-deoxycitidine and at least one aprotic solvent. The pharmaceutical compositions may further comprise at least one protic solvent. Also described are processes for preparing the pharmaceutical compositions and their use for the treatment of patients suffering from myelodysplastic syndromes.Type: GrantFiled: October 24, 2013Date of Patent: June 6, 2017Assignee: Fresenius Kabi Oncology LimitedInventors: Dhiraj Khattar, Rajesh Khanna, Sanjay Motwani, Sunny Chopra, Minakshi Garg
-
Patent number: 9643932Abstract: The present invention relates to an improved process for the synthesis of bendamustine, in particular, bendamustine hydrochloride of the formula (VI) and its intermediate 1-methyl-5-[bis(2-chloroethyl)amino]-1H-benzimidazol-2-yl]lithium butanoate of formula (V), both having a purity of ?99%, which is simple, convenient, economical, does not use hazardous chemicals and is industrially viable.Type: GrantFiled: December 19, 2014Date of Patent: May 9, 2017Assignee: Fresenius Kabi Oncology LimitedInventors: Bhuwan Bhaskar Mishra, Nikunj Shambhubhai Kachhadia, Vinod Singh Tomar, Saswata Lahiri
-
Patent number: 9440979Abstract: An improved process for the preparation of Pralatrexate which is less hazardous. The invention further relates to novel intermediates and process thereof useful for the preparation of Pralatrexate. The present invention also relates to a substantially pure Pralatrexate and a process for obtaining the same in high yield.Type: GrantFiled: July 18, 2013Date of Patent: September 13, 2016Assignee: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Saswata Lahiri, Nitin Gupta, Hemant Kumar Singh, Nilendu Panda, Vishal Handa, Azim Abul, Chandan Kumar Gupta, Sunil Sanghani, Ghanashyam Madhukar Sonavane
-
Patent number: 9421207Abstract: A pharmaceutical composition of Pemetrexed represented by formula (I), which is a liquid ready to use solution formulation or a lyophilized pharmaceutical composition for parenteral administration comprising a pharmaceutically acceptable organic amine, an inert gas and optionally containing at least one or more pharmaceutically acceptable excipients. Also provided are processes for preparation of the ready to use solution formulation or lyophilized pharmaceutical composition of the present invention.Type: GrantFiled: May 30, 2013Date of Patent: August 23, 2016Assignee: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Dhiraj Khattar, Rajesh Khanna, Mukti Yadav, Krishanu Burman
-
Patent number: 9199953Abstract: An amorphous form of cabazitaxel is disclosed. It is preferably characterized by an X-ray powder diffraction (XRD) pattern as depicted in FIG. 1. It is prepared by (a) preparing a solution of cabazitaxel in a suitable solvent and mixture thereof; and (b) recovering the amorphous forms of cabazitaxel from the solution by removal of the solvent.Type: GrantFiled: October 30, 2012Date of Patent: December 1, 2015Assignee: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Saswata Lahiri, Bhuwan Bhaskar Mishra, Vijay Ojha, Nilendu Panda, Sonu Prasad Shukla
-
Patent number: 9108924Abstract: The present invention relates to an improved process for the synthesis of bendamustine, in particular, bendamustine hydrochloride of the formula (VI) and its intermediate 1-methyl-5-[bis(2-chloroethyl)amino]-1H-benzimidazol-2-yl]lithium butanoate of formula (V), both having a purity of ?99%, which is simple, convenient, economical, does not use hazardous chemicals and is industrially viable.Type: GrantFiled: September 20, 2012Date of Patent: August 18, 2015Assignee: Fresenius Kabi Oncology LimitedInventors: Bhuwan Bhaskar Mishra, Nikunj Shambhubhai Kachhadia, Vinod Singh Tomar, Saswata Lahiri